Original document(19 pages)  中文版
    An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
Application Number
申请号
200580002037 Application Date
申请日
2005.01.06
Title 名称 Triaza-cyclopenta [cd] indene derivatives
Publication Number
公开号
1910187 Publication Date
公开日
2007.02.07
Approval Pub. Date Granted Pub. Date
International Classification 分类号 C07D487/16;A61K31/505;A61P25/00
Applicant(s) Name
申请人
Taisho Pharma Co., Ltd.
Address 地址
Inventor(s) Name 发明人 Nakazato Atsuro;Okubo Taketoshi;Nozawa Dai;Tamita Tomoko;Kennis Ludo E. J.
Attorney & Agent 代理人 long chun
More information 更  多  信  息


 Related patents information
Thiazole derivatives
Optically active substituted pheynylalkylamine derivatives
2-carbonylthiazole derivatives and use of the same
Aryloxyaniline derivatives
4-tetrahydropyridylpyrimidine derivatives
Nitrogen-containing tetracyclic compounds
Arylpiperidine derivatives and use thereof
Heteroaromatic derivatives
Fluorine-containing amino acid derivatives
Carbamoyl tetrahydropyridine derivatives
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.